Pharmaceuticals
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma")announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfullycompleted patient ...
2026-10-31 13:00
6068
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. J...
2026-10-31 00:00
3845
Nuance Pharma Announces First Patient Dosed in REACH Phase III Trial of STG320 (Actair®) in China
SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of house dust mite-induced allergic rhinitis in China. Stallergenes Greer's Actair® is a sublingual tablet cur...
2026-10-30 19:14
2904
Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa
EAST RUTHERFORD, N.J., Oct. 30, 2026 /PRNewswire/ -- Cambrex, a leading global
contract development and manufacturing organization (CDMO), today marked the
groundbreaking of its $120 million expansion at its Charles City, Iowa facility.
2026-10-30 18:00
2663
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29, 2026 ...
2026-10-30 09:00
3808
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precisionbispecific antibodies for immunology and inflammation, today announced the pricing of ...
2026-10-30 08:15
4521
Asymchem Completes its First USFDA Pre-Approval Inspection (PAI) of the Tianjin 4 TIDES Manufacturing Site
TIANJIN, China, Oct. 29, 2026 /PRNewswire/ -- Asymchem successfully completed its first U.S. Food and Drug Administration (USFDA) Pre-Approval Inspection (PAI) of Asymchem Life Science (Tianjin) Co., Ltd.'s TIDES development and manufacturing facility ("TJ4"), which took place between June 29th t...
2026-10-29 21:30
4610
OncoC4 Announces Oral Presentation of a Late-Breaking Abstract on Cesalatamig at the 41st Annual Meeting of SITC
— Global Phase 1/2 Study Data in PD-(L)1–Resistant/Refractory NSCLC to Be Presented on November 7, 2026 — — Clinical Oral Abstract Session 2 Begins at 1:45 PM MST — ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicin...
2026-10-29 21:30
5395
Yuyu Pharma Explores Animal Health as a New Pathway for Human Drug Innovation
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities ac...
2026-10-29 21:00
3008
SGH's AI tool wins international award for improving antibiotic use
SINGAPORE, Oct. 29, 2026 /PRNewswire/ -- Singapore General Hospital (SGH) has won the Silver Award in the Dr Prathap C Reddy Excellence Award for Clinical Quality and Patient Safety at the International Hospital Federation (IHF) Awards 2026, for its Augmented Intelligence in Infectious Diseases (...
2026-10-29 14:00
3140
Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease
TOKYO, Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NT...
2026-10-29 10:00
3015
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no platea...
2026-10-29 07:40
3020
Median PFS Approaches 14 Months! 3SBio's PD-1/VEGF Bispecific Antibody Posts Impressive Data at ESMO 2026
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- At the 2026 European Society for Medical Oncology (ESMO) Congress, 3SBio presented long-term follow-up results from a Chinese Phase II clinical study of SSGJ-707 combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (N...
2026-10-28 20:56
3190
Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad. The center was unveiled at the inaugural Jiahui International Cell The...
2026-10-28 14:41
2273
The Jumbophage Cocktail_Fighting Superbugs and Shrimp Disease
BANGKOK, Oct. 28, 2026 /PRNewswire/ -- What if a weapon against some of the world's most stubborn bacteria were hiding in the soil beneath our feet? Could these microscopic hunters help us confront antibiotic-resistant "superbugs" and bacterial diseases devastating shrimp? The answer may lie in u...
2026-10-28 14:24
2843
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment
Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's pharmaceuti...
2026-10-28 11:32
3657
Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services
GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...
2026-10-28 08:00
4212
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...
2026-10-28 08:00
4001
Piramal Pharma Limited Announces Results for Q2 and H1 FY27
MUMBAI, India, Oct. 27, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Cons...
2026-10-28 03:28
3282
Fios Genomics bioinformatics team and services move to Excelra
Edinburgh-based team joins Excelra's scientific consulting group, strengthening
its omics analytics expertise and presence in the UK and Europe
EDINBURGH, Scotland and HYDERABAD, India, Oct. 27, 2026 /PRNewswire/ --
Excelra
2026-10-27 23:00
2469
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
47318
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
22834
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
19772
